Interestingly, a recent study in mice showed that CXCR6 is highly expressed in intratumoral CD8+ T cells and that these cells are more immunocompetent and could enhance the effect of anti-PD-1 blockade to delay tumor progression (96). The gene discussed is CD8A; the disease is neoplasm.